They hope the website will be an unbiased source for genetic risk information, testing, and financial support services and spur cascade testing in families.
A recent $4 million grant will help double the size of the database, which is already helping researchers study links between genetic ancestry and cancer treatment outcomes.
New data for KRAS inhibitors in colorectal cancer show promising results when combined with EGFR inhibitors.
Two studies at the ESMO Congress highlighted unequal access to genetic testing for cancer patients and gaps in country-specific breast cancer risk guidelines in Europe.
After a retrospective analysis identified targeted treatment opportunities for this subset of patients, researchers began a Phase II trial of a MEK and BRAF inhibitor.
The company expects to begin regulatory talks with the FDA after it presents more mature data early next year.
Liquid biopsy was comparable to tissue-based NGS in assessing EGFR mutations in the study, leading researchers to highlight the benefit of using both to expand patient access.
The researchers attributed the increase to the availability and ease of liquid biopsy testing and doctors using NGS to profile difficult-to-treat subtypes.
TERT promoter mutations could help predict recurrence, guide treatment decisions, and be a target for precision oncology drugs, according to a new study.
TOPOGRAPH, which is still being validated, may help doctors match patients to precision treatment options based on clinical evidence, and regulatory and payment status.